Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2024-12-31 00:00:00 ET · period of report 2024-12-27 · accession 0001714899-24-000236 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-31 | 2024-12-27 | DNLI | Schuth Alexander O. | COFO, Sec | M - OptEx | $5.28 | +6,708 | 205.3K | +3% | +$35.4K |
| D | 2024-12-31 | 2024-12-27 | DNLI | Schuth Alexander O. | COFO, Sec | M - OptEx | $0.00 | -6,708 | 46.7K | -13% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-27 | M | A | 6,708 | $5.28 | 205,290 | D | — | — | (F1) Includes 118,810 Unvested RSUs. |
| 2 | Derivative | Stock Option (right to buy) | 2024-12-27 | M | D | 6,708 | $0.00 | 46,671 | D | $5.28 · — to 2027-03-07 | 6,708 Common Stock | (F3) 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. |